Welcome to our dedicated page for Pulmatrix news (Ticker: PULM), a resource for investors and traders seeking the latest updates and insights on Pulmatrix stock.
Pulmatrix Inc (PULM) is a clinical-stage biopharmaceutical company pioneering inhaled therapeutics through its proprietary iSPERSE™ dry powder delivery platform. This resource provides investors and industry stakeholders with comprehensive updates on the company's progress in developing treatments for respiratory diseases and central nervous system disorders.
Our curated news collection offers timely access to clinical trial developments, regulatory milestones, and strategic partnerships critical for evaluating PULM's growth trajectory. Track updates spanning pulmonary infection therapies, migraine treatment candidates, and technology licensing agreements that demonstrate the versatility of the iSPERSE platform.
Key content categories include progress reports on lead drug candidates, intellectual property expansions, and collaborative research initiatives. This centralized hub eliminates the need to monitor multiple sources, providing verified updates directly from corporate communications and validated industry reports.
Bookmark this page for efficient monitoring of Pulmatrix's advancements in engineered dry powder formulations and therapeutic applications. Regular visits ensure you maintain current awareness of material events influencing the company's position in the competitive inhaled therapeutics market.
Pulmatrix, Inc. (NASDAQ: PULM) announced the dosing of the first patient in a Phase 2b clinical trial for PUR1900, an inhaled treatment for Allergic Bronchopulmonary Aspergillosis (ABPA) and asthma. This double-blind, placebo-controlled study will assess the safety and efficacy of PUR1900 over 16 weeks, followed by an 8-week observation period. The trial aims to enroll 30 subjects across the U.S., U.K., Australia, and France. This milestone supports Pulmatrix's collaboration with Cipla and targets proof-of-concept data by mid-2024, potentially establishing PUR1900 as the first approved treatment for ABPA.
Pulmatrix, Inc. (NASDAQ: PULM) announces a virtual key opinion leader (KOL) event titled "PUR3100 for the Treatment of Acute Migraine: Unlocking Potential of DHE Treatment" on February 3, 2023, at 10:00 AM ET. The event features Dr. Stewart J. Tepper from Dartmouth College, discussing the treatment landscape for migraine patients and the clinical profile of dihydroergotamine (DHE). Dr. Margaret Wasilewski, CMO of Pulmatrix, will present recent Phase 1 data on PUR3100, an orally inhaled DHE delivered via Pulmatrix's patented iSPERSE™ technology. The event will include a live Q&A session.
Pulmatrix, Inc. (NASDAQ: PULM) announced that its abstract will be presented at the American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting from February 24-27, 2023 in San Antonio, Texas. The study focuses on PUR1800, an inhaled narrow-spectrum kinase inhibitor for chronic obstructive pulmonary disease (COPD). The presentation, by Margaret Wasilewski, MD, Chief Medical Officer, will summarize safety and tolerability results from a Phase 1b study. It is scheduled for a poster session on February 24 from 3:15 to 4:15 PM CST at the Convention Center, Lobby Level, Hall 2.
Pulmatrix, Inc. (NASDAQ: PULM) announced successful results from a Phase 1 trial of PUR3100, an inhaled dihydroergotamine formulation aimed at treating acute migraines. Conducted on 26 healthy subjects, the trial showed that PUR3100 was well-tolerated, with fewer gastrointestinal side effects compared to intravenous DHE. It achieved a five-minute Tmax and Cmax within the therapeutic range across all doses. The company plans to discuss findings with the FDA and prepare for a Phase 2 study, signaling progress in addressing a critical healthcare need for migraine treatment.
Pulmatrix, Inc. (PULM) reported Q3 2022 revenues of $1.9 million, a $0.8 million increase year-over-year. The rise was mainly due to revenue from the PUR1900 program. However, total revenues are down from $4.713 million in the nine months ended September 2021 to $4.363 million in the same period of 2022. R&D expenses rose $1.3 million to $5.3 million, largely driven by PUR1900 clinical costs. The company has $40.7 million in cash, expected to cover operations into Q2 2024, and is advancing both PUR3100 and PUR1900 towards pivotal trial stages.
Pulmatrix, Inc. (NASDAQ: PULM) announced the completion of dosing in a Phase 1 trial for PUR3100, an orally inhaled formulation of dihydroergotamine (DHE) for acute migraine treatment. The trial enrolled 26 healthy volunteers, assessing safety and pharmacokinetics across three dose groups. Phase 1 data is expected in Q4 2022. The company highlights a significant need for new options as 75% of migraine sufferers do not find relief with current medications. CEO Ted Raad expressed optimism for PUR3100's potential to be a best-in-class product.
Pulmatrix, Inc. (NASDAQ: PULM) reported financial results for Q2 2022, revealing a revenue decrease to $1.3 million from $2.2 million in Q2 2021. The net loss widened to $4.6 million compared to $3.9 million in the prior year. Cash and cash equivalents stand at $42.9 million, expected to sustain operations until Q2 2024. The company is advancing its therapies with PULM on track for Phase 2b study of Pulmazole in Q1 2023 and PUR3100 Phase 1 study underway, with data expected by Q4 2022.
Pulmatrix, Inc. (NASDAQ: PULM) announced the dosing of the first five subjects in a Phase 1 trial for PUR3100, an inhaled formulation of dihydroergotamine (DHE) aimed at treating acute migraines. The double-blind trial will assess the safety and pharmacokinetics of three doses of PUR3100 against IV DHE. This innovative approach could offer a more convenient alternative to current treatments. Results are expected in Q4 2022, which will inform future efficacy studies. The company aims for PUR3100 to be a best-in-class product for migraine therapy.
Pulmatrix, Inc. (NASDAQ: PULM) reported Q1 2022 results with $1.2 million in revenue, a decline from $1.4 million in Q1 2021. The company ended the quarter with $47.5 million in cash, extending its cash runway into Q2 2024.
Research and development costs increased to $4.1 million, while general administrative expenses rose to $2.0 million. The net loss for Q1 2022 was $4.973 million with a loss per share of $1.51. The Pulmazole Phase 2b study is slated to begin in Q1 2023, with top-line data expected in Q2 2024.
Pulmatrix, Inc. (NASDAQ: PULM) reported its 2021 financial results, revealing a revenue drop to $5.2 million from $12.6 million in 2020, attributed to lower collaboration revenues. Research and development expenses slightly decreased, while general and administrative costs also fell. The company raised $46.75 million in 2021 and has enough cash to fund operations through Q1 2024. Significant upcoming trials include a Phase 2b study for Pulmazole and a Phase 1 study for PUR3100. Pulmatrix also regained compliance for Nasdaq listing and appointed Dr. Margaret Wasilewski as Chief Medical Officer.
FAQ
What is the current stock price of Pulmatrix (PULM)?
What is the market cap of Pulmatrix (PULM)?
